Suneva Medical has signed a definitive merger agreement with Viveon Health Acquisition to create a new regenerative aesthetics company.
The combined company’s pro forma equity valuation is expected to be approximately $511m.
Under the deal, Viveon Health will provide 25 million shares to Suneva’s current security holders, who will also receive up to 12 million earn-out shares if the average share price reaches a certain benchmark in the five years following completion of the transaction.
Suneva CEO Pat Altavilla said: “We are excited to be partnering with Viveon Health as we step into the next phase of growth as a leader in the regenerative aesthetics sector supporting the needs of physicians and patients seeking proven and validated innovations.
“Our journey to this point has been paved with product innovation and clinical education led by an experienced team that brings a proven track record of sales growth and market development.”
Headquartered in the US, Suneva focuses on developing, producing and marketing new products for the regenerative medical aesthetic markets that meet the demands of both doctors and patients.
The company’s portfolio of products includes minimally invasive solutions that use the restorative capacity of the body in non-surgical outpatient treatment settings to provide immediate aesthetic results.
Suneva has developed multiple products, including PlasmaIQ, a handheld plasma energy device for skin rejuvenation, and Bellafill, a dermal filler for the correction of nasolabial folds and treatment of moderate to severe, atrophic, distensible facial acne scars on the cheeks.
Other products in the company’s portfolio are the Silhouette Instalift, a resorbable suture for cosmetic facial procedures; Puregraft, a unique fat grafting system; and Amplifine, a plasma (PRP) gel tube and syringe technology.
Subject to approval from Suneva and Viveon Health’s stockholders, as well as other customary closing conditions, the transaction is anticipated to conclude in the first half of the year.